ロード中...
Carcinoma of Unknown Primary with EML4‐ALK Fusion Response to ALK Inhibitors
With the advent of next‐generation sequencing (NGS) and precision medicine, investigators have determined that tumors from different tissue sources that have the same types of genetic mutations will have a positive response to the same targeted therapy. This finding has prompted us to seek potential...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6459257/ https://ncbi.nlm.nih.gov/pubmed/30679319 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0439 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|